Lake Street is pleased to announce that it served as sole bookrunner for TELA Bio, Inc. (NasdaqGM:TELA) in its offering of 4,600,00 shares of common stock at a public offer price of $8.00 per share for gross proceeds of $36.8 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including but not limited to research and development costs, manufacturing costs, the acquisition or licensing of other businesses, products or product candidates, working capital and capital expenditures.
TELA Bio, Inc. is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.
None of the information contained in this website constitutes a recommendation, solicitation or offer by Lake Street Capital Markets or its affiliates to buy or sell any securities, options or other financial instruments or provide any investment advice or service. Certain transactions give rise to substantial risk and are not suitable for all investors. Past performance does not guarantee future results.
920 Second Avenue South
Suite 700
Minneapolis, MN 55402
Copyright © 2020 Lake Street Capital Markets
